Breast Cancer Nos clinical trials

Explore recruiting breast cancer nos clinical trials.

Recruiting breast cancer nos studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Breast Cancer Nos trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)

Ireland, Hungary, France, Portugal, Sweden, Spain +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A translational RANDOMIZED phase III study exploring the effect of the addition of capecitabine to Carboplatinum based chemotherapy in early “triple negative” breast cancer

Sweden, Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

Pre-operative phase II trial for breast cancer with nivolumab in combination with novel IO (BELLINI trial)

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan+pembrolizumab vs. SoC chemotherapy in clinical stage II-III, triple-negative early breast cancer (ADAPT-TN-IV)

Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Open-Label, Single-Arm Study of Lirafugratinib in Patients With Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement

France, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase IIa Clinical Trial: Feasibility Study on Non-Invasive Simultaneous Hyperpolarized [1-13C]Pyruvate Magnetic Resonance Spectroscopy and 18F-FDG PET (hyperPET) for Metabolic Imaging in Patients with Cancer

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Breast Cancer Nos trials by city

Breast Cancer Nos in Toronto Breast Cancer Nos in Vancouver Breast Cancer Nos in Montreal Breast Cancer Nos in Calgary Breast Cancer Nos in Edmonton Breast Cancer Nos in Ottawa Breast Cancer Nos in Winnipeg Breast Cancer Nos in Quebec City Breast Cancer Nos in Hamilton Breast Cancer Nos in Kitchener Breast Cancer Nos in London Breast Cancer Nos in Halifax Breast Cancer Nos in New York Breast Cancer Nos in Los Angeles Breast Cancer Nos in Chicago Breast Cancer Nos in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease